Ultragenyx to allow generic DOJOLVI launch from Jan 1, 2033 under settlement

Ultragenyx sold a rare pediatric PRV for $203M, its second such sale in a week. The voucher was earned after FDA approval of FAYUVI for MPS IIIA. The buyer is undisclosed. The deal follows a $210M sale of another PRV, totaling $413M. The company plans to use the funds for R&D and profitability.

Ultragenyx Pharmaceutical (RARE) sold a $203M priority review voucher tied to its gene therapy Fayuvi's FDA approval, marking its second such sale this month. The company's P/S ratio is 2.1, below its historical median of 15.7, reflecting market skepticism. Its GF Score™ is 48/100, indicating mixed financial health. Insiders have sold $3.7M in shares over the past year.

Ultragenyx Pharmaceutical announced it will sell a rare pediatric disease priority review voucher for $203 million, following FDA approval of its treatment for mucopolysaccharidosis type IIIA. The deal is pending customary closing conditions, including antitrust review.

Ultragenyx Pharmaceutical (RARE) sold a priority review voucher for $203M, received after FDA approval of its rare disease therapy, Fayuvi. The agreement was announced Wednesday.

Ultragenyx (RARE) will sell a Rare Pediatric Disease Priority Review Voucher for $203M, received after FDA approval of FAYUVI. The deal, advised by Jefferies, aims to fund rare disease therapies and improve profitability. Shares fell 1.07% to $14.76 in early trading.

Ultragenyx sold a priority review voucher for rare pediatric diseases to an undisclosed buyer for $203 million. The voucher, granted by the FDA, can expedite the review of a future drug application. Ultragenyx's stock has declined 35.13% year-to-date.